Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Five Period Crossover Study of the Ability of Late Sodium or Calcium Current Block (Mexiletine, Lidocaine, or Diltiazem) to Balance the Electrocardiographic Effects of hERG Potassium Current Block (Dofetilide or Moxifloxacin)

NCT02308748 is registered in ClinicalTrials.gov with Food and Drug Administration (FDA) as lead sponsor.

NCT NCT02308748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02308748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Five Period Crossover Study of the Ability of Late Sodium or Calcium Current Block (Mexiletine, Lidocaine, or Diltiazem) to Balance the Electrocardiographic Effects of hERG Potassium Current Block (Dofetilide or Moxifloxacin)
Lead sponsor
Food and Drug Administration (FDA)
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2014
Completion date
June 30, 2014
Enrollment
22 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

drug-induced qt prolongation, pharmacodynamics, pharmacokinetics